您当前的位置：首页 > 主题内容 > 临床麻醉 > 专家评述
Awakening Concentration of Desflurane Is Decreased in Patients with Obstructive Jaundice
时间：2010-08-24 09:11:26 来源： 作者：
THAT there is a relation between the functional status of the liver and that of the brain has been known for centuries.1The most widely recognized aspect of this relation is that hepatocellular failure may be complicated by the syndrome of hepatic encephalopathy, in which neurotransmission in the brain is altered.2–4Recently, it has been suggested that some extremely common complaints among patients with cholestatic liver disease, such as fatigue and pruritus, might also be associated with altered neurotransmission in the brain.5–13 Because accumulating evidence has suggested that inhaled anesthetics exert their effects via acting on ion channels and receptors on the neuronal cell membrane and altering synaptic transmission in the central nervous system,14–16 this altered neurotransmission in the brain might affect the sensitivity of cholestatic patients to inhaled anesthetics. However, this hypothesis has not been confirmed in cholestatic patients. For the inhaled anesthetics, the minimum alveolar concentration (MAC) for achieving a 50% probability of no response to a verbal command (MACawake) provides one measure of hypnotic potency. Accordingly, we designed this study to determine whether the MACawakeof desflurane in patients with obstructive jaundice undergoing surgical treatment has been changed and to evaluate the relation between MACawakeand serum concentrations of total bilirubin, bile acids, alanine transaminase, and albumin. Materials and Methods After receiving approval from our local ethics committee (Shanghai, China), informed consent was obtained from each patient undergoing elective surgery for hepatobiliary disease. Twenty-four patients with obstructive jaundice (serum total bilirubin > 20μM) caused by neoplasm of the bile duct or the head of the pancreas were included in the study. Twenty nonjaundiced patients who had chronic cholecystitis or liver hemangioma served as controls. All patients had American Society of Anesthesiologists physical status I or II and were aged between 50 and 70 yr. Exclusionary criteria were (1) age older than 70 yr or younger than 50 yr; (2) significant obesity (body mass index > 30 kg/m2); (3) a history of cardiovascular, respiratory, or renal disease; (4) hepatic encephalopathy, psychiatric illness, or neuropathy; (5) acid– base disturbance, blood electrolyte dysfunction, diabetes, sepsis, or obvious weight loss caused by carcinoma; (6) medications known to affect MACawakeor a history of either alcohol or drug abuse; and (7) excitement with desflurane induction. Each patient fasted for 12 h and did not receive any sedative or analgesic drugs before anesthesia. Intravenous access was established, and patients were monitored with electrocardiography, pulse oximetry, and nasopharyngeal temperature and invasive blood pressure measurement. Inspired and expired concentrations of desflurane, carbon dioxide, and oxygen were measured
continuously using a Datex respiratory gas analyzer (Datex Instrumentarium Corp., Helsinki, Finland) calibrated by a standard gas mixture before anesthesia for each patient. The test of MACawakefor each patient was determined using a modification of the method of Chortkoff et al.17 All patients spontaneously breathed 100% oxygen through a clear, plastic, tight-fitting facemask attached to a semiclosed anesthetic circuit via a 95-ml dead space (used to protect the end-tidal samples from contamination by inspired gas). Anesthetic administration began with a single-step increase to the initial target end-tidal concentration of 1.4%. This and subsequent steps were maintained for 15 min to allow adequate time for alveolar and brain desflurane partial pressures to equilibrate. Then, a designated observer blinded to the patients’ clinical conditions, the patient group, and the anesthetics administered asked the patient in a normal tone to open his or her eyes, repeating the request not more than three times. If he or she made an appropriate response, the anesthetic concentration was increased by 0.1% and again kept constant for 15 min. The process was repeated until an end-tidal concentration was reached at which the patient did not respond appropriately to command. The MACawakefor each patient was the concentration midway between the value permitting the response (opening eyes on request) and that just preventing the response. When MACawakehad been determined, samples of arterial blood were collected for analysis of blood gas tensions, and samples of venous blood were collected for measurements of liver biochemistries. Then, anesthesia was deepened to a level appropriate for the surgical procedure. Values are presented as mean ±SD. The Student unpaired t test was used for analysis of variance between the groups. Using SPSS 10.1.4 for Windows (SPSS Inc., Chicago, IL), multiple regression was used to determine whether total bilirubin, alanine transaminase, bile acids, or albumin correlated significantly with MACawake of obstructive jaundiced patients for desflurane. P < 0.05 was considered statistically significant. In addition, we had measured the MACawake of five jaundiced patients and five nonjaundiced patients in the preliminary trial.Consequently, based on the difference between two groups, the formula for normal theory, and assuming a two-sided type I error protection of 0.05 and a power of 0.80, 20 patients in each group were required to reveal a statistically significant difference. Results There were no significant differences between the two groups with respect to age, weight, sex, or body temperature (table 1). No episodes of hypotension (systolic blood pressure < 90 mmHg), bradycardia (heart rate < 60 beats/min), hypoxemia, hypothermia, depression of respiration, or acid– base disturbance occurred during the course of measurement of MACawake.The MACawakeof desflurane for patients with obstructive jaundice (1.78 ±0.19%) was significantly less than that observed for the control group (2.17 ±0.25%; P < 0.001). Multiple regression analysis showed that there was a high negative correlation between serum total bilirubin and MACawake, whereas alanine transaminase, bile acids, and albumin did not significantly correlate with MACawake (table 2). The equation of the regression line for desflurane was MACawake (%) ＝2.041 －0.00094· total bilirubin (μM), with R2of 0.444 (fig. 1).   Discussion Our study showed that the MACawakeof desflurane for patients with obstructive jaundice decreased significantly compared with that of nonjaundiced controls (P < 0.001);moreover, there was a high negative correlation between serum total bilirubin and MACawake(r ＝－0.67,P < 0.0004). Calculus, stricture, and neoplasm are the main causes of extrahepatic biliary obstruction. Obstructive jaundice caused by calculus or stricture is often accompanied by cholangitis or sepsis. Moreover, the level of jaundice often sharply fluctuates based on the status of primary hepatobiliary disease. It is reported that sepsis can decrease the requirements of inhaled anesthetic.18To avoid the possible influences of sepsis and fluctuation of jaundice on MACawake, we excluded these patients from the study. Although neoplasm can induce obvious weight loss, which may also affect anesthetic requirements, these symptoms had not been present in patients we enrolled. The observer was blinded to the patients’ group, individual clinical conditions, and the anesthetics administered, but it was not feasible to blind the investigator as to whether the patient had obstructive jaundice because jaundiced patients show obviously yellow color. However, because the observer was not aware of our study design and our aim of determining the relation between obstructive jaundice and the sensitivity to inhaled anesthetic, we think that the physician bias was minimal. The MACawakevalue of 2.17 ±0.25% desflurane for our nonjaundiced patients aged 50–69 yr was smaller than that of 2.60 ±0.46% desflurane for healthy volunteers aged 21–30 yr reported previously by Chortkoff et al.17 using a similar method to determine the values of MACawake. Considering the influence of age on MACawake that each increasing decade of life is associated with a 6.7% decrease in MACawake, 19 this discrepancy can be primarily attributed to the different ages of populations enrolled in the studies. In addition, we used the endpoint of eye opening, whereas Chortkoff et al. used the endpoint of response to the command to squeeze the investigator’s hands, which could also result in some discrepancy. In this study, we determined MACawake using ascending sequences of anesthetic concentrations. As guides to predicting relative times to awakening, data using descending sequences may seem more relevant. However, Jones et al.20found no difference in values using ascending versus descending sequences of anesthetic concentrations for the endpoints of MACawakefor desflurane. We maintained constant end-tidal concentrations of desflurane for 15 min. Theoretically, the time required for the brain to reach the same partial pressures as that in blood depends on the blood–brain partition coefficient. Based on laboratory investigation on tissue homogenates, 2195% equilibration between arterial blood and brain partial pressures for halothane and enflurane should be completed in 14.4 and 7.9 min, respectively. Considering that desflurane has the lowest solubility of the modern clinically used volatile anesthetics, 15 min of steady state end-tidal concentrations of desflurane should allow adequate equilibration among the lung, the arterial blood, and the brain. The mechanism of decreased awakening concentration of desflurane is unclear. Many pathophysiologic conditions can affect potency of inhaled anesthetics, including additional anesthetic drugs; differences in core temperature, age, hypotension, and acid– base status22–25; and diseases such as hypothyroidism or hyperthyroidism, 26 diabetes, 27 and sepsis, 18 but these conditions did not occur in our patients. Because the elimination of inhaled anesthetics is predominately determined by the lung, rather than the liver, and desflurane possesses a relatively low solubility in blood and minimal metabolism in humans, its pharmacokinetic characteristics are unlikely to be changed significantly in patients with obstructive jaundice, even though liver function is impaired. Because it is known that anesthetic-induced hypnosis and amnesia are mediated primarily within the brain,28changes in the functional status of the brain consequentto the obstructive jaundice seem to be more likely toincrease hypnotic potency of desflurane. Recently, it has been suggested that altered neurotransmission may occur in the brains of cholestatic patients. For example, some evidence suggests that pruritus and fatigue complicating cholestasis may be the consequence of a central mechanism, specifically increased opioidergic neurotransmission9–13and defective serotoninergic neurotransmission.5–8 The latter is considered to be sensitive to inhaled anesthetics.29,30Consequently,the altered neurotransmission in patients with obstructive jaundice may, at least in part, contribute to the reduction of anesthetic requirements. However,whether other neurotransmissions are also involved in the reduction of desflurane MACawake of jaundiced patients should be studied further, given the association of inhaled anesthetics with altered activity of a variety of neuronal ion channels, particularly the fast synaptic neurotransmitter receptors such as nicotinic acetylcholine, _-aminobutyric acid type, and glutamate receptors.31–33 Besides altered neurotransmission in the brain, the direct damage to the brain of obstructive jaundice may also play a role in decreasing the requirements of desflurane. An experimental observation in a well-characterized canine model of cholestasis secondary to bile duct resection provides histologic evidence that neurologic damage, such as simple atrophy and pyknosis of nerve cells, neuronophagia, and ghost cells, was observed in the brain. Moreover, the range of neurologic damage spread from the basal ganglia, putamen, and red nucleus to the thalamus, cerebral cortex, and substantia nigra, with the duration of obstructive jaundice prolonged.34 In conclusion, our study demonstrates that the MACawake of desflurane was significantly reduced in obstructive jaundiced patients compared with nonjaundiced controls; moreover, there is a highly inverse relation between the concentration of serum total bilirubin and the MACawakeof desflurane in jaundiced patients. Altered neurotransmission and neurotoxicity of jaundice in the brain may partly contribute to the reduction of anesthetic requirement. The authors thank Victor C. Baum, M.D. (Professor, Departments of Anesthesiology and Pediatrics and the Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia), for his review of the manuscript and some suggestions. References 1. Frerichs FT: A Clinical Treatise on Diseases of the Liver. Vol 1. Translated by Murchison C. London, New Sydenham Society, 1860, pp 193–246 2. Basile AS, Jones EA, Skolnick P: The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacol Rev 1991; 43:27–71 3. Butterworth RF: The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996; 16:235–44 4. Jones EA, Weissenborn K: Neurology and the liver. J Neurol Neurosurg Psychiatry 1997; 63:279–93 5. Jones EA: Fatigue associated with chronic liver disease: A riddle wrapped in a mystery inside an enigma. Hepatology 1995; 22:1606–8 6. Jones EA, Yurdaydin C: Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 1997; 25:492–4 7. Swain MG, Maric M: Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 1997; 25:291–4 8. Burak KW, Le T, Swain MG: Increased midbrain 5-HT1A receptor number and responsiveness in cholestatic rats. Brain Res 2001; 892:376–9 9. Bergasa NV, Jones EA, Skolnick P: The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995; 108:1582–8 10. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA: Effects of naloxone infusions in patients with the pruritus of cholestasis: A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123:161–7 11. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA: Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992; 103:630–5 12. Bergasa NV, Alling DW, Vergalla J, Jones EA: Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994; 20:85–90 13. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA: Central mu-opioid receptors are down-regulated in a rat model of acute cholestasis. J Hepatol 1992; 15:220–4 14. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci 1999; 55:1278–303 15. Franks NP, Lieb WR: Molecular and cellular mechanisms of general anaesthesia. Nature 1994; 367:607–14 16. Pocock G, Richards CD: Excitatory and inhibitory synaptic mechanisms in anaesthesia. Br J Anaesth 1993; 71:134–47 17. Chortkoff BS, Eger EI II, Crankshaw DP, Gonsowski CT, Dutton RC, Ionescu P: Concentrations of desflurane and propofol that suppress response to command in humans. Anesth Analg 1995; 81:737–43 18. Allaouchiche B, Duflo F, Debon R, Tournadre JP, Chassard D: Influence of sepsis on minimum alveolar concentration of desflurane in porcine model. Br J Anaesth 2001; 87:280–3 19. Eger EI II: Age, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awake. Anesth Analg 2001; 93:947–53 20. Jones RM, Cashman JN, Eger EI II, Damask MC, Johnson BH: Kinetics and potency of desflurane (I-653) in volunteers. Anesth Analg 1990; 70:3–7 21. Eger EI II, Larson CP: Anaesthetic solubility in blood and tissues: Values and significance. Br J Anaesth 1964; 36:140–4 22. Vitez TS, White PF, Eger EI II: Effects of hypothermia on halothane MAC and isoflurane MAC in the rats. ANESTHESIOLOGY 1974; 41:80–1 23. Stevens WC, Dolan WM, Gibbons RT, White A, Eger EI II, Miller RD, deJong RH, Elashoff RM: Minimum alveolar concentration (MAC) of isoflurane with and without nitrous oxide in patients of various ages. ANESTHESIOLOGY 1975; 42:197–200 24. Munson ES, Hoffman JC, Eger EI II: Use of cyclopropane to test generality of anesthetics requirement in the elderly. Anesth Analg 1984; 63:998–1000 25. Quasga AL, Eger EI II, Tinker J: Determination and applications of MAC. ANESTHESIOLOGY 1980; 53:315–34 26. Muson ES, Hoffman JC, DiFazio CA: The effects of acute hypothyroidism and hyperthyroidism on cyclopropane requirement (MAC) in rats. ANESTHESIOLOGY 1968; 29:1094–8 27. Brain JE, Bogan L, Kennedy RH, Seifen E: The impact of streptozotocininduced diabetes on the minimum alveolar anesthetic concentration (MAC) of inhaled anesthetics in the rat. Anesth Analg 1993; 77:342–5 28. Eger EI II, Koblin DD, Harris RA, Kendig JJ, Pohorille A, Halsey MJ, Trudell JR: Hypothesis: Inhaled anesthetics produce immobility and amnesia by different mechanisms at different sites. Anesth Analg 1997; 84:915–8 29. Yamakura T, Harris RA: Effects of gasenous anesthetic nitrous oxide and xenon on ligand-gated ion channels: Comparison with isoflurane and ethanol. ANESTHESIOLOGY 2000; 93:1095–101 30. Jenkins A, Franks NP, Lieb WR: Actions of general anaesthetics on 5-HT3 receptors in N1E-115 neuroblastoma cells. Br J Pharmacol 1996; 117:1507–15 31. Franks NP, Lieb WR: Which molecular targets are most relevant to general anaesthesia? Toxicol Lett 1998; 100–101:1–8 32. Mennerick S, Jevtovic-Todorovic V, Todorovic SM, Shen W, Olney JW, Zorumski CF: Effects of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci 1998; 18:9716–26 33. Narahashi T, Aistrup GL, Lindstrom JM, Marszalec W, Nagata K, Wang F, Yeh JZ: Ion channel modulation as the basis for general anesthesia. Toxicol Lett 1998; 100–101:185–91 34. Furukawa Y: Histological changes in the brain due to experimental obstructive jaundice. Nippon Geka Gakkai Zasshi 1991; 92:37–45 |
|
|
[!--temp.pl--]